Table 2.
Additional clinical information regarding lung function and BAL cell content
| Group | VC | FEV1 | DLCO | Macrophages | Lymphocytes | Neutrophils | Eosinophils | CD4/CD8 ratio | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | [%] | N | [%] | N | [%] | N | [%] | N | [%] | N | [%] | N | [%] | N | ||
| Discovery | ||||||||||||||||
| Asthma | 17 | 107 (65–123) | 17 | 103 (82–126) | 0 | NA | 17 | 86 (70–95) | 17 | 11 (4–26) | 17 | 1.4 (0–5.4) | 17 | 0.8 (0–13) | 0 | NA |
| Control | 1 | 110 (110–110) | 16 | 114 (86–130) | 0 | NA | 16 | 88 (66–97) | 16 | 7 (2–28) | 16 | 1.8 (0–6.8) | 16 | 0.2 (0–1.4) | 13 | 2 (1–5) |
| Löfgren’s syndrome | 12 | 88 (81–96) | 12 | 90 (66–100) | 10 | 95 (62–139) | 18 | 74 (48–94) | 18 | 22 (6–46) | 18 | 1 (0–5.8) | 18 | 0.1 (0–1.6) | 18 | 8 (1–26) |
| Non-Löfgren’s syndrome | 13 | 81 (66–104) | 14 | 79 (48–104) | 10 | 80 (53–128) | 17 | 75 (42–97) | 17 | 23 (3–58) | 17 | 0.8 (0–15.2) | 17 | 0 (0–1.2) | 17 | 6 (2–25) |
| Verification | ||||||||||||||||
| Control | 9 | 108 (76–140) | 14 | 106 (65–135) | 0 | NA | 14 | 89 (60–96) | 14 | 9 (3–39) | 14 | 0.9 (0.4–2.2) | 14 | 0 (0–0.6) | 8 | 7 (1–37) |
| Löfgren’s syndrome | 85 | 91 (57–118) | 87 | 90 (52–120) | 72 | 89 (56–126) | 101 | 74 (34–98) | 101 | 23 (2–65) | 101 | 1 (0–14.4) | 100 | 0.2 (0–13.3) | 100 | 6 (1–33) |
| Non-Löfgren’s syndrome | 80 | 86 (53–124) | 87 | 87 (32–140) | 59 | 87 (48–136) | 96 | 75 (22–96) | 96 | 23 (2–75) | 96 | 1.4 (0–14.6) | 96 | 0.2 (0–7.6) | 94 | 5 (0–31) |
The number of individuals indicate the availability of data for the respective parameters. Data represented as median (minimum-maximum) unless stated otherwise
VC vital capacity, FEV1 forced expiratory volume in one second, DLCO diffusion capacity of the lung for carbon monoxide, NA not analysed